Anti-diabetic compounds

US9163227B2 · kind B2 · utility

Assignee

• CovX Technologies Ireland Limited · IE

Inventors

• Gopinath Vedachalam Annathur · Bengaluru, IN
• Palani Balu · Cupertino, US
• Rory F. Finn · Ballwin, US
• Jie Huang · Taoyuan, TW
• Olivier Alexandre Laurent · San Diego, US
• Nancy Levin · Encinitas, US
• Nicholas Luksha · North Andover, US
• Joseph Patrick Martin, Jr. · Wildwood, US
• Haim Moskowitz · San Diego, US
• Moorthy Sitharamaiah Suriyanarayana Palanki · Encinitas, US
• Mark Pozzo · Chesterfield, US
• Gregory Allan Waszak · O'Fallon, US
• Jin Xie · Bositenghu, CN

Key dates

• Filing date: Dec 12, 2012
• Grant date: Oct 20, 2015
• Expiry date: Jan 11, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a composition of the formula: [FGF21-1st Linker]-[Ab]-[2nd-Linker-Ex4]; wherein FGF21 is an FGF21 homologue; and Ex4 is an Exendin4 homologue; and Ab is an aldolase catalytic antibody or antigen binding portion thereof; and the 1st linker is covalently attached to the side chain of a protein-linking residue in FGF21 and to a combining site of the antibody, and the 2nd linker is covalently attached to the side chain of a peptide-linking residue in Ex4 and to a combining site of the antibody, and wherein the first and second linker are the same or different. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.